{
    "clinical_study": {
        "@rank": "163303", 
        "arm_group": [
            {
                "arm_group_label": "FSS first, then FCI", 
                "arm_group_type": "Experimental", 
                "description": "At each of two treatment visits participants fast for 10 hours before dosing, and receive naltrexone before and after dosing.  Participants in this group receive a single dose of fentanyl sublingual spray (FSS) at the first visit.  After a washout period of at least seven days, they receive a single intramuscular fentanyl citrate injection (FCI) at the second treatment visit."
            }, 
            {
                "arm_group_label": "FCI first, then FSS", 
                "arm_group_type": "Experimental", 
                "description": "At each of two treatment visits participants fast for 10 hours before dosing, and receive naltrexone before and after dosing. Participants in this group receive a single intramuscular fentanyl citrate injection (FCI) at the first visit.  After a washout period of at least seven days, they receive a single dose of fentanyl sublingual spray (FSS) at the second treatment visit."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to compare the rate of absorption and bioavailability of\n      fentanyl sublingual spray 400 mcg to fentanyl citrate 100 mcg by intramuscular injection."
        }, 
        "brief_title": "Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Bioavailability", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meets protocol-specified criteria for qualification and contraception\n\n          -  Good access to veins on both sides\n\n          -  Willing and able to remain confined in the study unit for the entire duration of each\n             treatment period and comply with restrictions related food, drink and medications\n\n          -  Voluntarily consents to participate and provides written informed consent prior to\n             any protocol-specific procedures\n\n        Exclusion Criteria:\n\n          -  Intolerance to venipuncture or injections\n\n          -  Presence or history of oral disease, irritation or piercings\n\n          -  Allergy or adverse response to fentanyl, naltrexone, or related drugs\n\n          -  Tattoos, scarring, or other skin abnormality at planned injection sites\n\n          -  History or current use of over-the-counter medications, dietary supplements, or drugs\n             (including nicotine and alcohol) outside protocol-specified parameters\n\n          -  Signs, symptoms or history of any condition that, per protocol or in the opinion of\n             the investigator, might compromise: 1) the safety or well-being of the participant or\n             study staff; 2) the safety or well-being of the participant's offspring (such as\n             through pregnancy or breast-feeding); 3) the analysis of results"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02138396", 
            "org_study_id": "INS-13-019"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "FSS first, then FCI", 
                    "FCI first, then FSS"
                ], 
                "description": "A single dose of fentanyl, 400 mcg per sublingual spray", 
                "intervention_name": "Fentanyl Sublingual Spray (FSS)", 
                "intervention_type": "Drug", 
                "other_name": "Subsys\u00ae"
            }, 
            {
                "arm_group_label": [
                    "FSS first, then FCI", 
                    "FCI first, then FSS"
                ], 
                "description": "A single dose of fentanyl citrate, 100 mcg per intramuscular injection", 
                "intervention_name": "Fentanyl Citrate Injection (FCI)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "FSS first, then FCI", 
                    "FCI first, then FSS"
                ], 
                "description": "Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.", 
                "intervention_name": "Naltrexone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Citric Acid", 
                "Naltrexone", 
                "Fentanyl"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78217"
                }, 
                "name": "Worldwide Clinical Trials Early Phase Services, LLC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Single-Dose, Open-Label, Two-Period, Two-Treatment, Two-Sequence Crossover Exploratory Bioavailability Study of Subsys\u00ae (Fentanyl Sublingual Spray), 400 mcg, and Fentanyl Citrate Injection 2 mL x 0.05 mg/mL (Total Dose 100 mcg) Under Fasted Conditions", 
        "overall_official": {
            "affiliation": "Worldwide Clinical Trials Early Phase Services, LLC", 
            "last_name": "George J Atiee, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Maximum concentration (Cmax) by mode of administration", 
            "safety_issue": "No", 
            "time_frame": "within 36 hours after dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02138396"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the concentration-time curve [AUC(last)] by mode of administration", 
                "safety_issue": "No", 
                "time_frame": "prior to the intial dose, at 5, 10, 20, 30, and 40 minutes postdose, and at 1.0, 1.25, 1.5,  2.0, 4.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, and 36 hours post-dose"
            }, 
            {
                "measure": "Area under the curve extrapolated to infinity [AUC(inf)] by mode of administration", 
                "safety_issue": "No", 
                "time_frame": "prior to the intial dose, at 5, 10, 20, 30, and 40 minutes postdose, and at 1.0, 1.25, 1.5,  2.0, 4.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, and 36 hours post-dose"
            }
        ], 
        "source": "INSYS Therapeutics Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "INSYS Therapeutics Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}